[
  {
    "ts": "2026-02-10T00:23:54+00:00",
    "headline": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
    "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
    "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "67b2f8ee-e066-32bb-a421-7d4a55fb3212",
      "content": {
        "id": "67b2f8ee-e066-32bb-a421-7d4a55fb3212",
        "contentType": "STORY",
        "title": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
        "pubDate": "2026-02-10T00:23:54Z",
        "displayTime": "2026-02-10T00:23:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]